Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

  • Etude concernée: IFCT-1102
  • Auteurs / Authors: Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet P.J
  • Journal / Conference: ESMO open
  • Année / Year: 2018
  • PMID: 30094074
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/30094074
  • PDF: IFCT-1102_Bucil.pdf